Pancreatic Cancer Research

ResearcherHammersmith HospitalActive in the last 2 years

Long R. Jiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6774-4280; OpenAlex author ID A5069234120. Sources: OpenAlex.

Their work

Papers
31 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 4 papers · 2014: 3 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 31

  1. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  2. Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/as9.0000000000000486↗
  3. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  4. Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16020452↗
  5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  6. Graphene Sensor Arrays for Rapid and Accurate Detection of Pancreatic Cancer Exosomes in Patients' Blood Plasma Samples. Co-author DOI 10.1021/acsnano.3c01812↗
  7. Immunological combination treatment holds the key to improving survival in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03332-5↗
  8. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ajpath.2018.03.020↗
  9. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  10. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma? Co-author DOI 10.1080/14737159.2019.1622414↗
  11. Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? Last author DOI 10.18632/oncotarget.26511↗
  12. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  13. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Last author DOI 10.18632/oncotarget.24873↗
  14. Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9. Co-author DOI 10.1038/s41598-017-14688-z↗
  15. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Co-author DOI 10.1038/mt.2016.60↗
  16. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.ejca.2015.04.006↗
  17. Pancreatic cancer: current understanding of molecular and genetic aetiologies. Last author DOI 10.1136/postgradmedj-2014-133161↗
  18. Pancreatic cancer: current management and treatment strategies. Last author DOI 10.1136/postgradmedj-2014-133222↗
  19. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. Last author DOI 10.1001/jamasurg.2013.3643↗
  20. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Co-author DOI 10.1586/14737159.2014.893192↗
  21. Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma. Last author DOI 10.1586/17474124.2014.881251↗
  22. Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker? Last author DOI 10.1586/14737159.2013.845091↗
  23. Towards a clinical use of miRNAs in pancreatic cancer biopsies. Co-author DOI 10.1586/erm.12.136↗
  24. Is there a 'margin' for error in pancreatic cancer surgery? Last author DOI 10.2217/fon.12.175↗
  25. Circulating molecular markers in pancreatic cancer: ready for clinical use? Last author DOI 10.2217/fon.12.187↗
  26. Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11605-012-1985-4↗
  27. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Last author DOI 10.1016/j.pan.2012.03.057↗
  28. The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2012.03.021↗
  29. Loss of miR-126 is crucial to pancreatic cancer progression. Last author DOI 10.1586/era.12.67↗
  30. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Co-author DOI 10.2217/pgs.12.73↗
  31. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1586/era.11.184↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Enver Frampton · 21 shared papers, 2011–2024 · strength 1.38
  2. Jonathan Krell · 16 shared papers, 2011–2024 · strength 0.95
  3. Tamara Gall · 12 shared papers, 2013–2019 · strength 0.73
  4. Leandro Castellano · 12 shared papers, 2011–2019 · strength 0.64
  5. David Cunningham · 3 shared papers, 2023–2024 · strength 0.63
  6. Justin Stebbing · 12 shared papers, 2011–2019 · strength 0.58
  7. Elisa Giovannetti · 7 shared papers, 2014–2024 · strength 0.58
  8. Ricky Harminder Bhogal · 2 shared papers, 2024 · strength 0.51
  9. Kai Tai Derek Yeung · 2 shared papers, 2024 · strength 0.51
  10. Nagy Adley Habib · 6 shared papers, 2012–2020 · strength 0.42
  11. Daniel Liu · 3 shared papers, 2019–2024 · strength 0.41
  12. Harpreet Singh Wasan · 4 shared papers, 2015–2023 · strength 0.40
  13. Katharine L. Aitken · 1 shared paper, 2024 · strength 0.23
  14. Niccola Funel · 3 shared papers, 2015–2019 · strength 0.18
  15. Zaynab Jawad · 2 shared papers, 2017–2018 · strength 0.17
  16. Mikael Hans Sodergren · 2 shared papers, 2014–2020 · strength 0.17
  17. Duncan R.C. Spalding · 3 shared papers, 2012–2019 · strength 0.17
  18. Mahrou Vahabi · 1 shared paper, 2024 · strength 0.16
  19. Benoît Immordino · 1 shared paper, 2024 · strength 0.16
  20. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.16
  21. Jisce R. Puik · 1 shared paper, 2024 · strength 0.16
  22. Marc G. Besselink · 1 shared paper, 2024 · strength 0.16
  23. Luca Morelli · 1 shared paper, 2024 · strength 0.16
  24. Geert Kazemier M · 1 shared paper, 2024 · strength 0.16
  25. Rutger‐Jan Swijnenburg · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.